U.S. Markets close in 28 mins
  • S&P 500

    4,240.20
    -7.24 (-0.17%)
     
  • Dow 30

    34,280.02
    -199.58 (-0.58%)
     
  • Nasdaq

    14,125.19
    +55.76 (+0.40%)
     
  • Russell 2000

    2,321.25
    -14.55 (-0.62%)
     
  • Crude Oil

    70.90
    -0.01 (-0.01%)
     
  • Gold

    1,867.30
    -12.30 (-0.65%)
     
  • Silver

    28.02
    -0.13 (-0.45%)
     
  • EUR/USD

    1.2123
    +0.0016 (+0.1333%)
     
  • 10-Yr Bond

    1.5010
    +0.0390 (+2.67%)
     
  • Vix

    16.82
    +1.17 (+7.48%)
     
  • GBP/USD

    1.4109
    -0.0007 (-0.0508%)
     
  • USD/JPY

    110.0840
    +0.4490 (+0.4095%)
     
  • BTC-USD

    39,549.39
    +2,119.72 (+5.66%)
     
  • CMC Crypto 200

    987.45
    +18.61 (+1.92%)
     
  • FTSE 100

    7,146.68
    +12.62 (+0.18%)
     
  • Nikkei 225

    29,161.80
    +213.07 (+0.74%)
     

Gilead Sciences Announces Second Quarter 2021 Dividend

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors has declared a cash dividend of $0.71 per share of common stock for the second quarter of 2021. The dividend is payable on June 29, 2021, to stockholders of record at the close of business on June 15, 2021. Future dividends will be subject to Board approval.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

For more information on Gilead, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210429005960/en/

Contacts

Jacquie Ross, Investors
(650) 358-1054